Amsbio has announced the availability of ultraspecific and extensively validated monoclonal antibodies under the UltraMAB brand.
Screening of candidate antibodies against greater than 10,000 human proteins, using a state-of-the-art High Density Protein Microarray Platform, has resulted in the identification of the most specific monoclonal antibodies (UltraMAB antibodies) available for cancer biomarkers and other important diagnostic targets.
Performance and specificity are key pre-requisites for antibodies to be used for diagnostic and therapeutic applications. To ensure the superior performance, every UltraMAB monoclonal antibody is validated according to the scientific findings and the medical records of related diseases. Major applications of validation include Western Blot, Immunohistochemical staining with over 25 types of normal and cancer human tissues, Immunocytochemistry/Immunofluorescence, and Fluorescence-Activated Cell Sorting.
Some commonly used alternative diagnostic antibodies perform well in applications but cross-react with other unrelated proteins.This cross-reactivity may potentially cause unexpected side effects and generate false diagnostic reports for clinicians.
By contrast, each UltraMAB is validated, and determined to have no cross reactivity with other human proteins other than the antibody’s intended target protein as determined by analysis on a 10K High Density Protein Microarray Platform. Consequently, each UltraMAB is quality control verified, guaranteeing superior performance for applications,where specificity-verification and the highest quality antibodies are critical for accurate detection.
